EMERYVILLE, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GRANITE-001 for the treatment of …
Tag Archives: Gritstone Oncology
December, 2018
August, 2018
-
23 August
bluebird bio and Gritstone Oncology Collaborate to Develop Novel Cancer Cell Therapies
CAMBRIDGE, Mass. & EMERYVILLE, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell …
July, 2018
-
19 July
Bristol-Myers Squibb and Gritstone Oncology Partner to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
EMERYVILLE, Calif. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001, which comprises sequential delivery of neoantigens to patients within an adenovirus-based vector (prime) and a self-replicating …
May, 2016
-
9 May
Immune Design and Gritstone Oncology Partner to Develop Personalized Immunotherapies
SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, and Gritstone Oncology, a private cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced a clinical collaboration for development of novel, personalized immunotherapies combining …